Q2 FY2026 Earnings
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Starling Oncology(STLN) the Revenue is 161.28 M (+34.62%), Beat estimate;the EBIT is -4.616 M (+58.83%), Beat estimate;the EPS is -0.08 (+46.67%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.16B34.62%
0.16B29.55%
+0.01B5.07%
EBITExceed expectations
-0.00B58.83%
-0.00B55.97%
+0.00B2.86%
EPSMiss expectations
-0.0846.67%
-0.06457.33%
-0.016010.66%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf